On October 24, 2022 Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) in areas of high unmet medical need, reported that it will present preclinical data from its targeted protein degrader programs at the 5th Annual Targeted Protein Degradation Summit, being held October 25-28, 2022, in Boston, Massachusetts (Press release, BioTheryX, OCT 24, 2022, View Source [SID1234622324]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leah Fung, Ph.D., Chief Scientific Officer of Biotheryx, will present as a Keynote Plenary Speaker in a session, "Highlighting Key Discoveries of Bifunctional Degraders to New Targets," to highlight novel small molecule bifunctional degraders of son of sevenless homolog 1 (SOS1), potent inhibitors of Kirsten rat sarcoma (KRAS) mutant cancers. Aparajita Chourasia, Ph.D., Vice President of Biology of Biotheryx will also present the latest preclinical data in support of the Company’s BTX-1188 molecular glue program targeting GSPT1 and IKZF1/3.

"We are looking forward to sharing findings at the TPD Summit that highlight the potential of our innovative PRODEGY platform to develop new and exciting cancer therapies," said Dr. Fung. "The data Biotheryx are presenting are evidence of our team’s commitment to the discovery and design of first-in-class protein degraders."

On October 24, 2022 KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, reported that Dr. Stephen Thorne, Co-Founder and CSO, will present data on its product candidate VET3-TGI at the 14th International Oncolytic Virotherapy Conference (IOVC), taking place October 23-26, 2022, in Karuizawa, Nagano, Japan (Press release, KaliVir Immunotherapeutics, OCT 24, 2022, View Source [SID1234622323]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VET3-TGI is based on KaliVir’s unique Vaccinia Enhanced Template (VET) platform, capable of generating potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and enhance intravenous delivery and spread. VET3-TGI incorporates modifications granting the expression of CXCR3, IL-12 and a TGF-β inhibitor, allowing for efficient trafficking to the tumor, activation of anti-tumor immune responses and inhibition of immunosuppressive activity.

On October 24, 2022 PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, reported that the Company is invited at upcoming Jefferies 2022 London Healthcare Conference. Jefferies is scheduled to be held in London from November 15-17, 2022 (Press release, PharmAbcine, OCT 24, 2022, View Source [SID1234622322]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

Event: Jefferies 2022 London Healthcare Conference
Date: November 15-17, 2022
Event Calendar: View Source

Jefferies London Healthcare Conference is one of the largest healthcare-dedicated conference in Europe. In the past conference, over 550 companies and 3,000 attendees from Americas, Europe, Middle East, Africa, and Asia have joined the event.

At Jefferies, Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine, will hold meetings with registered members of the investor community to look for investment opportunities and discuss the current trends in drug development and healthcare sector. The registered members will include leading global executives, institutional investors, and private equity investors.

To schedule a one-on-one meeting with PharmAbcine, contact the assigned Jefferies representative.

On October 24, 2022 Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development, and manufacturing of antibody-based therapeutics, reportes that the management team will participate in four upcoming investor conferences in October and November 2022 as follows (Press release, Transcenta, OCT 24, 2022, View Source [SID1234622321]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1) 2022 Listed Companies Roadshow Conference* Season 3 (Pharmaceutical and Biological Industry)

Time: Tuesday, October 25, 2022—Thursday, October 27, 2022

Online one-on-one meeting/group meeting

Organizer: Essence International Financial Holdings Limited &

Sullivan International Limited & Roadshow China;

2) 2022 DJSeedin Innovation Partnering Conference

Time: Thursday,November 03, 2022—Friday, November 04, 2022

Mandarin Oriental Pudong Shanghai

Organizer: PharmaDJ&bioSeedin

3) 2022 IDEAS Summit

Time:Tuesday, November 08, 2022—Friday, November 11, 2022 (9:30am -18:00pm)

Online one-on-one meeting/group meeting

Organizer: Wonderful Sky

4) Goldman Sachs Asia Pacific Healthcare Forum 2022 (Virtual)

Time:Tuesday, November 15, 2022—Friday, November 18, 2022

Online one-on-one meeting/group meeting

Organizer: Goldman Sachs

On October 24, 2022 Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, reported that the management team will participate in and attend one-on-one meetings at two investor conferences in November 2022 as follows (Press release, Gracell Biotechnologies, OCT 24, 2022, View Source [SID1234622320]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Credit Suisse 31st Annual Healthcare Conference 2022
One-on-one meetings: Tuesday, November 8, 2022
Location: Rancho Palos Verdes, CA

Jefferies London Healthcare Conference 2022
Fireside Chat: November 15 at 2:40 pm GMT
One-on-one meetings: Tuesday, November 15, 2022
Location: London, UK

A webcast of the fireside chat will be available on the News and Events section of Gracell’s investor website. A replay of the webcast will be available for 30 days following the event.